RxDoctor Payments Data

Melinda Rogers

Nurse Practitioner · Summerfield, FLNPI 1801268529

Payments from drug & device makers

$1,935in general payments, 2019–2025

Across 80 payments — averaging $24.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$663
  • Stryker$173
  • Ironshore Pharmaceuticals Inc.$154
  • AstraZeneca$154
  • Teva Pharmaceuticals USA, Inc.$114
  • Lilly USA, LLC$83
  • plus $596 from 17 others

What the payments were for

  • Food & beverage$1,935100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,935 in reported general payments places this provider in the 80th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$12,893
Medicare patients
28
Services billed
121

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban23$22,041
MounjaroTirzepatide19$19,512
OzempicSemaglutide12$13,445
XareltoRivaroxaban11$7,962
Albuterol Sulfate HfaAlbuterol Sulfate69$1,968
Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine11$1,587
Ventolin HfaAlbuterol Sulfate14$1,294
Levothyroxine Sodium81$1,152
Gabapentin76$963
Azithromycin66$847
Atorvastatin Calcium119$790
FenofibrateFenofibrate Nanocrystallized32$715
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip25$613
Metoprolol Succinate45$559
Losartan Potassium62$545

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$83$19,51219 claims
Novo NordiskOzempic$36$13,44512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Summerfield

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →